Beyond the Dow Euphoria
As we break out the Dow all-time high party gear, I started digging for ideas that might not be playable today but are setting up for the near future.Sarepta (SRPT) Source: StockCharts.com View Chart » View in New Window »
First is Serapta Pharmaceuticals (SRPT), a biotech. There are always huge risks with biotech companies outside of the technicals. The key is to define and limit the risks. Disclaimers aside, this stock looks fantastic on a close above $32. From a technical standpoint, a run to $38 is possible. I'm not going to get into the potential here as Adam Feuerstein has this well-covered, but I do like the name regardless of the technicals. However, basing a buy on the technicals via calls feels like the right approach. Biotechs generally shrug off any high correlation to the markets, so a correction in equities may not matter much. That will be important to some folks....157 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.